Antibiotic Incentives: Advocates Sounding The Alarm For DISARM

Antibiotic developers have a blunt message for Congress: the time for action is now or never. They see a targeted reimbursement change (The DISARM Act) as vital to send a signal to investors that the sector can be saved – and don’t want to delay to debate other ideas like “subscription” models.

Security alarm keypad with person arming the system concept for crime prevention - Image
Can Congress find the right reimbursement code in time to rescue the antibiotics industry?

Antibiotic drug developers and infectious disease specialists are pushing for immediate enactment of legislation to carve-out new antibiotics from inpatient payments to help preserve the pipeline of new therapies while longer term solutions are debated.

“The time to kick the can down the road has passed,” Antimicrobials Working Group representative Jeff Stein (CEO of

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

More from Pink Sheet